NCT03861273

Phase 3, Open-label, Single-arm Study to Evaluate Efficacy and Safety of FIX Gene Transfer With PF-06838435 (rAAV-Spark100-hFIX-R338L) in Adult Male Participants With Moderately Severe to Severe Hemophilia B (FIX:C ≤2%) (BeneGene-2)

Study Summary

This study will evaluate the efficacy and safety of PF-06838435 (a gene therapy drug) in adult male participants with moderately severe to severe hemophilia B (participants that have a Factor IX circulating activity of 2% or less). The gene therapy is designed to introduce genetic material into cells to compensate for missing or non-functioning Factor IX. Eligible study participants will have completed a minimum 6 months of routine Factor IX prophylaxis therapy during the lead in study (C0371004). Participants will be dosed once (intravenously) and will be evaluated over the course of 6 years. The main objective of the study will evaluate the annualized bleeding rate \[ABR\] for participants treated with gene therapy versus standard of care (SOC) therapy (FIX prophylaxis replacement regimen).

Want to learn more about this trial?

Request More Info

Interventions

PF-06838435/ fidanacogene elaparvovecBIOLOGICAL
Gene Therapy

Study Locations

FacilityCityStateCountry
UCSF IDS PharmacySan FranciscoCaliforniaUnited States
University of California, San Francisco - Clinical Research CenterSan FranciscoCaliforniaUnited States
University of California, San Francisco - Outpatient Hematology ClinicSan FranciscoCaliforniaUnited States
The Regents of the University of California, San Francisco campusSan FranciscoCaliforniaUnited States
Hemophilia and Thrombosis Center at the University of Colorado Anschutz Medical CampusAuroraColoradoUnited States
Regents of the University of Colorado University of Colorado Denver, Office of Grants and ContractsAuroraColoradoUnited States
Indiana Hemophilia & Thrombosis Center, Inc.IndianapolisIndianaUnited States
Indiana Hemophilia and Thrombosis Center, IncIndianapolisIndianaUnited States
Innovative Hematology, Inc.IndianapolisIndianaUnited States
St. Vincent Hospital & Health Care Center, Inc.IndianapolisIndianaUnited States
Madison Radiological GroupMadisonMississippiUnited States
Mississippi Center for Advanced MedicineMadisonMississippiUnited States
Center for Human Phenomic SciencePhiladelphiaPennsylvaniaUnited States
Investigational Drug ServicePhiladelphiaPennsylvaniaUnited States
Penn Blood Disorder CenterPhiladelphiaPennsylvaniaUnited States
The Trustees of the University of Pennsylvania, Office of Clinical Research- LegalPhiladelphiaPennsylvaniaUnited States
Royal Prince Alfred HospitalCamperdownNew South WalesAustralia
Royal Adelaide HospitalAdelaideSouth AustraliaAustralia
The Alfred HospitalMelbourneVictoriaAustralia
Fiona Stanley HospitalMurdochWestern AustraliaAustralia
Royal Brisbane and Women's HospitalHerstonAustralia
Centro Estadual de Hemoterapia e Hematologia Marcos Daniel Santos - HemoesVitóriaEspírito SantoBrazil
Centro de Hematologia e Hemoterapia - Hemocentro de Campinas - UNICAMPCampinasSão PauloBrazil
Hospital das Clinicas da Faculdade de Medicina da Universidade de Sao PauloSão PauloSão PauloBrazil
Instituto Estadual de Hematologia Arthur de Siqueira Cavalcanti- HEMORIORio de JaneiroBrazil
McMaster University Medical Centre - Hamilton Health SciencesHamiltonOntarioCanada
Juravinski Hospital - Hamilton Health SciencesHamiltonOntarioCanada
St. Michael's HospitalTorontoOntarioCanada
Hopital Cardiologique Louis Pradel - CRTHBronFrance
Hopital NeckerParisFrance
Vivantes Klinikum FriedrichshainBerlinGermany
Vivantes Klinikum im FriedrichshainBerlinGermany
Universitätsklinikum Bonn Institut für Klinische Chemie und Klinische Pharmakologie -Phase 1-EinheitBonnGermany
Universitätsklinikum Bonn, Anstalt des öffentlichen RechtsBonnGermany
Universitätsklinikum BonnBonnGermany
General Hospital of Athens "LAIKO", 2nd Regional Blood Transfusion CenterAthensGreece
Azienda Ospedaliero Universitaria CareggiFlorenceItaly
Azienda Ospedaliera Universitaria Federico IINaplesItaly
Sapporo Tokushukai HospitalSapporoHokkaidoJapan
Nara Medical University HospitalKashiharaNaraJapan
Saitama Medical University HospitalIruma-gunSaitamaJapan
National Center for Child Health and DevelopmentSetagaya-kuTokyoJapan
King Abdulaziz Medical City-Ministry of national guardRiyadhKingdom of Saudi ArabiaSaudi Arabia
King Faisal Specialist Hospital and Research CentreRiyadhSaudi Arabia
King Abdullah International Medical Research CenterRiyadhSaudi Arabia
Kyung Hee University Hospital at GangdongSeoulSouth Korea
Hospital Universitario Virgen de la ArrixacaEl PalmarMurciaSpain
Hospital Universitari Vall d´HebrónBarcelonaSpain
Skåne University Hospital, Department of Hematology, Oncology and Radiation PhysicsMalmoSweden
ApoEx ABMalmoSweden
Changhua Christian HospitalChanghuaTaiwan
Kaohsiung Medical University Chung-Ho Memorial HospitalKaohsiung CityTaiwan
Chung Shan Medical University HospitalTaichungTaiwan
Chung Shan Medical UniversityTaichungTaiwan
Taichung Veterans General HospitalTaichungTaiwan
National Taiwan University HospitalTaipeiTaiwan
Acibadem Adana HospitalAdanaTurkey (Türkiye)
Gaziantep University Sahinbey Training and Research HospitalGaziantepTurkey (Türkiye)
Istanbul University Oncology InstituteIstanbulTurkey (Türkiye)
Ege University Medical Faculty HospitalIzmirTurkey (Türkiye)
Newcastle upon Tyne Hospitals NHS FTNewcastle upon TyneTYNE & WEARUnited Kingdom
Newcastle upon Tyne Hospitals NHS FTNewcastle upon TyneTYNE & WEARUnited Kingdom
Glasgow Royal InfirmaryGlasgowUnited Kingdom
Guy's and St. Thomas' NHS Foundation TrustLondonUnited Kingdom
Newcastle upon Tyne Hospitals NHS Foundation TrustNewcastle upon TyneUnited Kingdom

Official Trial Information

View on ClinicalTrials.gov

Data sourced from ClinicalTrials.gov. Last updated: April 14, 2026